The interaction between tumors and their microenvironments leads to a vicious cycle, which strengthens both immune suppression and cancer progression. The present study demonstrates for the first time that tumor-associated dendritic cells (TADCs) are a source of resistin, which is responsible for increasing lung cancer epithelial-to-mesenchymal transition. In addition, large amounts of resistin in the condition medium (CM) of TADCs increase cell migration and invasion, as well as the osteolytic bone metastatic properties of lung cancer cells. Neutralization of resistin from TADC-CM prevents the advanced malignancyinducing features of TADC-CM. Significantly elevated levels of resistin have been observed in mice transplanted with lung cancer cells, tumor-infiltrating CD11c + DCs in human lung cancer samples and lung cancer patients' sera. Induction of lung cancer progression by TADC-derived resistin is associated with increased expression of Wolf-Hirschhorn syndrome candidate 1 (WHSC1), a histone methyltransferase. Resistin-induced WHSC1 increases the dimethylation of histone 3 at lysine 36 and decreases the trimethylation of histone 3 at lysine 27 on the promoter of Twist, resulting in an enhancement of the expression of Twist. Knockdown of WHSC1 by small interfering RNA transfection significantly decreases resistin-mediated cancer progression by decreasing the upregulation of Twist, suggesting that WHSC1 plays a critical role in the regulation of Twist by epigenetic modification. Furthermore, mice that received antiresistin antibodies showed a decreased incidence of cancer development and metastasis. These findings suggest that TADC-derived resistin may be a novel candidate in promoting the development of lung cancer.
Introduction
Lung cancer has been one of the most common causes of death worldwide for several decades (1, 2) . Despite significant advances in treatment, improving the therapeutic outcome remains a serious problem due to the cancer's high molecular variety and drug resistance (3) . The tumor microenvironment has increasingly been recognized as a critical factor that protects the cancer from host immunity, promotes tumorigenesis and supports tumor growth and metastasis (4, 5) . The cells surrounding the tumors consistently release various soluble factors, such as growth and proinflammatory factors, which facilitate tumor development (6, 7) . Our previous studies have demonstrated that lung cancer cells promote immune tolerance through inhibiting the differentiation and maturation of dendritic cells (DCs) (8) . Lung tumor-associated dendritic cells (TADCs) have been shown to display an immune-suppression phenotype and to express the epidermal growth factor family, which in turn increase cancer progression (9) . However, it is still not fully understood whether TADCs express other protumorigenic factors responsible for lung cancer development, or precisely which molecules contribute to the interactions between the tumor cells and TADCs in the tumor microenvironment. Strategies that aim at the immune system, in combination with therapies targeting cancer cells, are invaluable to finding optimal responses in treating this devastating disease.
Epithelial-to-mesenchymal transition (EMT) is a process characterized by loss of epithelial phenotypes, and which acquires migratory, mesenchymal properties. EMT causes cancer cells to acquire the critical features of neoplasms, including loss of contact inhibition, deregulated growth control and increased invasiveness, thereby increasing their metastatic potential (10) . Twist, one of the major inducers of EMT, acts by reducing E-cadherin expression and increasing fibronectin levels (11, 12) . Epigenetic regulation is thought to contribute to changes in Twist expression via histone modification (13) . Recent study has demonstrated that the histone methyltransferase, Wolf-Hirschhorn syndrome candidate 1 (WHSC1), modulates Twist expression by increasing dimethylation of histone H3 at lysine 36 (H3K36me2), resulting in EMT in prostate cancer (14) . Methylation of histone at lysine residues promotes or prevents the binding of transcription factors and other proteins that access particular regions of the genome, resulting in the regulation of the transcriptional potential of the underlying genes (15, 16) . Therefore, we hypothesized that WHSC1 may play a pivotal role in mediating lung cancer progression by Twist upregulation via epigenetic regulation.
Resistin, a 12.5 kDa cysteine-rich secreted protein, is found in a screen for adipocyte gene products that are reduced by the antidiabetic drug rosiglitazone and increased in diet-induced and genetic forms of obesity (17) . Resistin is characterized by a unique structure of 10-11 cysteine residues, also known as resistin-like molecules (17, 18) . The expression and secretion of resistin by human mononuclear cells are markedly induced by inflammatory stimuli, and levels of resistin in humans have been shown to correlate strongly with circulating markers of inflammatory cytokines such as interleukin (IL)-1b, IL-6, IL-8, IL-12 and tumor necrosis factor-α (18) (19) (20) . Inflammation has increasingly been recognized as playing a pathogenic role in cancer (21) . Recent studies have shown that higher concentrations of resistin are found in patients with esophageal squamous cell carcinoma when compared with controls. In addition, resistin levels have been shown to gradually increase with tumor progression (22) (23) (24) . However, the role of resistin in lung cancer has not been studied previously.
In the current study, we found that TADCs, which produce high levels of resistin, play a protumorigenic role in the development of lung cancer. We also investigated the role of DCs in infiltrating tumor tissues of mice and human patients. Our results show that TADCderived resistin enhances A549 cell migration and invasion, and EMT via the paracrine effect. Furthermore, treatment of mice with antiresistin antibodies reduces the incidence of lung tumors. This study is the first to demonstrate that TADC-derived resistin promotes lung cancer progression, and may therefore be an attractive target in the development of therapeutic strategies targeting immune cells in the cancer microenvironment.
Material and methods

Lung cancer cells and conditioned media
Human lung cancer cells A549 were obtained from the American Type Culture Collection (number CCL-185) and cultured in Kaighn's modification (F12K) medium containing 10% fetal bovine serum (FBS). The human lung adenocarcinoma cell line CL1-5 was generously provided by Dr Pan-Chyr Yang of the Department of Internal Medicine, National Taiwan University Hospital and cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco BRL, Life Technologies) (25, 26) . To obtain the condition medium (CM) of A549 and CL1-5, cells were seeded at 2 × 10 6 cells/100 mm dish and cultivated for 24 h. The medium was replaced and the supernatants were harvested after 48 h of incubation.
Serum samples from lung cancer patients
Preoperative blood samples were obtained from 46 lung cancer patients and 24 healthy donors admitted to the Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Serum was separated by centrifugation and frozen at −80°C. Approval for this study was obtained from the Institutional Review Board of Kaohsiung Medical University Hospital, and informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
Isolation of CD14
+ monocytes and differentiation of monocyte-derived DCs Monocytes were purified from peripheral blood mononuclear cells obtained from healthy consenting donors. Mononuclear cells were isolated from blood by Ficoll-Hypaque gradient (GE Healthcare Bio-Sciences, Little Chalfont, UK). CD14 + monocytes were purified using CD14 + monoclonal antibody-conjugated magnetic beads (MACS MicroBeads; Miltenyi Biotec), according to the manufacturer's protocol. Monocyte-derived DCs (mdDCs) were generated by culturing CD14 + monocytes in RPMI 1640 medium containing 10% FBS (Invitrogen, Carlsbad, CA), 20 ng/ml granulocyte-macrophage colony-stimulating factor and 10 ng/ml IL-4 (R&D Systems, Minneapolis, MN) for 5 days. The medium was replaced with fresh medium containing granulocyte-macrophage colony-stimulating factor and IL-4 on day 3. For maturation of the DCs, immature mdDCs were stimulated with lipopolysaccharides (100 ng/ml) after priming with interferon-γ for 3 h. A549 tumor-associated mdDCs (A549-TADCs) and CL1-5-TADCs were generated by culturing CD14 + monocytes in RPMI 1640 medium containing FBS, granulocytemacrophage colony-stimulating factor and IL-4 presenting in A549, or CL1-5-CMs then stimulated as described above. After washing, the supernatant was collected and defined as A549-TADC-CM and CL1-5-TADC-CM. Supernatants from TADC and mdDC were collected. Resistin was quantified using a DuoSet enzyme-linked immunosorbent assay kit.
Analysis of cell proliferation, migration and invasion
Cell proliferation was assessed using Premixed WST-1 Cell Proliferation Reagent (Clontech Laboratories, Mountain View, CA) according to the manufacturer's instructions. Cell migration and invasion assays were conducted using wound-healing, a QCM™ 24-well Cell Migration Assay and an Invasion System, as described previously (15) . Resistin (1 or 10 ng/ml) was added to the bottom wells for 48 h as the chemoattractant, and the fluorescence of the invading cells was read using a fluorescence plate reader at excitation/emission wavelengths of 485/530 nm. The migration of A549 cells was also assessed using a scratch wound-healing assay.
For the blocking study, lung cancer cells were seeded in the upper insert and treated with or without rabbit antihuman resistin antibody or rabbit immunoglobulin G (2 μg/ml) (Phoenix Pharmaceuticals, Belmont, CA), and various TADC-CMs (20%) were added to the lower well to act as attractive agents. Migratory and invasive cells were quantified as described above.
Real-time quantitative reverse transcription-PCR and chromatin immunoprecipitation RNA isolation was performed using TRIzol reagent (Invitrogen). Complementary DNA was prepared using an oligo (dT) primer and reverse transcriptase (Takara, Shiga, Japan) following standard protocols. Real-time PCR was performed using SYBR Green on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). Each PCR reaction mixture contained 200 nM of each primer, 10 μl of 2x SYBR Green PCR Master Mix (Applied Biosystems) and 5 μl cDNA and RNase-free water, with a total volume of 20 μl. The PCR reaction was carried out with a denaturation step at 95°C for 10 min, then 40 cycles at 95°C for 15 s and finally at 60°C for 1 min. All PCRs were performed in triplicate and normalized to internal control glyceraldehyde-3-phosphate dehydrogenase messenger RNA (mRNA). Relative expressions were presented using the 2 −ΔΔCT method.
Chromatin immunoprecipitation was performed using an Agarose chromatin immunoprecipitation Kit (Pierce, Rockford, IL). Immunoprecipitated DNA was analyzed by quantitative PCR as described above, using SYBR Green dye. The primers used in this study have been described previously (14) .
Immunoblot
Cells were lysed on ice for 15 min using M-PER lysis reagent (Pierce). Cell lysate was centrifuged at 14 000g for 15 min, and the supernatant fraction was collected for immunoblotting. Equivalent amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (8-12%) and transferred to polyvinylidene difluoride membranes. After blocking for 1 h in 5% non-fat dry milk in Trisbuffered saline, the membrane was incubated with the desired primary antibody for 1-16 h. The membrane was then treated with the appropriate peroxidase-conjugated secondary antibody and the immunoreactive proteins were detected using an enhanced chemiluminescence kit (Millipore) according to the manufacturer's instructions.
Immunofluorescence
Non-cancerous lung tissue specimens obtained from human lung cancer patients were embedded in OCT (Tissue-Tek®, Torrance, CA) and frozen in liquid nitrogen. Sections (3-5 μm) were fixed with acetone at −20°C and then blocked by 2% normal goat serum/phosphatebuffered saline. The tissue sections were stained with rabbit antihuman resistin antibodies (Phoenix Pharmaceuticals) or co-stained with mouse anti-CD11c antibodies (Abcam). After washing with phosphate-buffered saline containing 0.1% Tween-20, the slides were incubated with Dylight 488-or Dylight 549-conjugated secondary antibodies (Rockland, Gilbertsville, PA), with 4′,6-diamidino-2-phenylindole (DAPI), for 1 h at room temperature. The data were analyzed with a confocal laser scanning microscope (Fluoview FV1000; Olympus, Tokyo, Japan).
Osteoclast differentiation and activity assay
Peripheral blood mononuclear cells were plated and incubated overnight at 37°C. Non-adherent cells were removed by washing with phosphate-buffered saline, and the remaining adherent cells were grown in culture medium containing mdDC-CM, or resistin (10 ng/ ml) presenting in 200 ng/ml human macrophage colony-stimulating factor and 100 ng/ml human receptor activator of nuclear factor kappa-B ligand for 21 days. The medium was replaced every 3 days. Osteoclast formation was measured by quantifying the positively stained cells by tartrate-resistant acid phosphatase (TRAP) (Sigma-Aldrich, St Louis, MO). Osteoclasts were determined to be TRAP-positive staining multinuclear (>3 nuclei) cells by means of light microscopy. The TRAP-positive cells and the number of nuclei per TRAP-positive cell in each well were counted. Osteoclast bone resorption activity was assessed using a bone resorption assay kit (Cosmo Bio, Tokyo, Japan), in the same culture conditions as described above.
Gene knockdown by siRNA Cells were transfected with MISSION® siRNA Universal Negative Controls, WHSC1 or Twist1 siRNA (Sigma-Aldrich). Immunoblot analyses showed that expression of WHSC1 and Twist1 remained low but detectable, whereas expression of glyceraldehyde-3-phosphate dehydrogenase was unaffected by siRNA treatment.
Animal models and isolation of CD11c
+ cells from lungs Lewis lung carcinoma (LLC) cells were transplanted into C57BL/6 mice via tail vein injections. Lung tissue was collected 14 days after the injections, then minced and incubated in RPMI 1640 medium with collagenase type 1 (400 U/ml) (Worthington Biochemicals) for 1 h at 37°C. The digested tissues were filtered through a 70 μm cell strainer and washed with RPMI 1640 medium. CD11c + DCs were isolated from the cell suspension by CD11c magnetic beads (Miltenyi Biotec), and the expressions of various mRNAs were assayed by quantitative reverse transcription-PCR (qRT-PCR). Cancer metastasis of lungs of the mice injected with LLC cells was evaluated. To determine the effect of resistin elevation on cancer development, recombinant mouse resistin (0.33 mg/kg) (R&D Systems) was administered by intraperitoneal injection four times every 5 days after transplantation. For blocking experiment, isotype control immunoglobulin G and goat polyclonal anti-mouse resistin antibodies (33 μg/mice) (Fitzgerald Industries International, North Acton, MA) were intraperiotenally injected three times, once every 7 days, after the administration of LLC. The animals were killed on day 24 after LLC transplantation, and the number of tumor nodules was recorded to analyze lung cancer incidence.
Statistical analysis
Data were expressed as means ± SD. Statistical comparisons of the results were made using analysis of variance. Significant differences (P < 0.05) between the means of the two test groups were analyzed using the Student's t-test.
Results
High levels of resistin were expressed in the process of DC differentiation from CD14
+ monocytes We previously demonstrated that lung cancer cells stimulate DCs to release soluble factors that enhance cancer cell progression (9, 27 ). In the current study, the microarray data showed that A549-TADCs express up to 10.56-fold levels of resistin when compared with DCs (Supplementary Figure 1A , available at Carcinogenesis Online). qRT-PCR analysis also showed that A549-CM and CL1-5-CM increase the expression of resistin in A549-TADCs and CL1-5-TADCs (Supplementary Figure 1B , available at Carcinogenesis Online). In addition, the protein levels of resistin are enhanced in A549 and CL1-5-TADCs, as determined by enzyme-linked immunosorbent assay analysis ( Figure 1A) . Furthermore, coculture of lung cancer cells with DCs also increases the expression of resistin in DCs at mRNA and protein levels (Supplementary Figure 1C , available at Carcinogenesis Online and Figure 1B) .
High levels of resistin in CD11c
+ DCs are found in the tumor sections of lung cancer-bearing mice and human lung cancer patients To evaluate the tumorigenic properties of TADC-derived resistin in vivo, we investigated whether mouse TADCs were also able to secrete resistin. We injected mouse lung cancer cell line LLC into mice, and then allowed the cells to develop for 14 days. CD11 + DCs were isolated from the lung tumors of the LLC-bearing mice. qRT-PCR analysis showed that lung tumor-infiltrated CD11c + DCs produce elevated levels of resistin in mRNA ( Figure 1C ). Enzyme-linked immunosorbent assay data also revealed that lung tumor-infiltrated CD11c + DCs generate high amounts of resistin when compared with CD11c + DCs obtained from normal mice ( Figure 1D) .
To confirm the role of resistin on TADC-mediated cancer progression in humans, we characterized the expression of resistin in tumor-infiltrated CD11c + DCs. Immunofluorescence staining of the marginal regions of a human lung cancer specimen revealed the presence of many CD11c + DCs, which had infiltrated the area around the tumor. These areas express higher levels of resistin in comparison with tissue sections of non-tumorous regions ( Figure 1E ). Furthermore, a marked statistical difference in resistin levels has been found between lung cancer patients and serum from healthy donors ( Figure 1F ).
Resistin contributes to TADC-mediated cancer migration, invasion, EMT and osteoclastogenesis
We then determined the effect of resistin on the proliferation, migration and EMT in A549 and CL1-5 cells. As shown in Supplementary  Figure 2 , available at Carcinogenesis Online, 72 h of treatment of lung cells with resistin did not increase proliferation of A549 and CL1-5 cells but did enhance the migration and invasion ability of these cells (Figure 2A-C) . In addition, resistin also causes A549 and CL1-5 cells to undergo EMT, including the downregulation of epithelial markers (E-cadherin and claudin-3) and upregulation of fibroblast markers (vimentin, fibronectin and N-cadherin) after 24 h of treatment ( Figure 2D ). Levels of Twist, an important regulator of EMT, increase in resistin-treated A549 and CL1-5 cells after 6 h of treatment ( Figure 2D ). Furthermore, resistin also increases the differentiation and activity of osteoclasts, which contribute to osteolytic metastases ( Figure 2E and 2F) .
To better understand the role of resistin, we blocked its effect by using specific neutralization antibodies. As shown in Figure 3A and B, TADC-CM increases the migration and invasion of A549 and CL1-5 cells. These effects are prevented by treatment with antihuman resistin antibodies but not by an isotype control ( Figure 3A and B). Similarly, the induction of A549-TADC-CM or CL1-5-TADC-CM on EMT and Twist expression is also inhibited by antihuman resistin antibodies ( Figure 3C ). The stimulatory effects of TADC-CMs on osteoclast differentiation are also inhibited by antihuman resistin antibodies ( Figure 3D ). These data clearly show that TADC-derived resistin mediates changes in lung cancer progression.
Resistin increases the expression of WHSC1 and changes the global methylation of histone protein
To ascertain how resistin promotes lung cancer progression, we determined the gene profile of resistin-treated A549 cells using a microarray. The data show that resistin increases 36 and decreases 275 gene expressions. Among these upregulated genes, levels of WHSC1, an oncogenic histone lysine methyltransferase, increased 3.12-fold in resistin-treated A549 cells ( Figure 4A ). qRT-PCR analysis also showed that resistin increases the expression of WHSC1 mRNA in both A549 and CL1-5 cells (Supplementary Figure 3 , available at Carcinogenesis Online). The protein levels of WHSC1 were also enhanced in resistin-treated A549 and CL1-5 cells after 6 h treatment, as determined by immunoblot analysis ( Figure 4B ). Furthermore, resistin treatment increases the dimethylation of H3K36 and decreases trimethylation of H3K27 in both A549 and CL1-5 cells ( Figure 4B ).
Resistin increases Twist expression through WHSC1-mediated epigenetic regulation
Elevated levels of WHSC1 have been reported to increase the expression of cancer invasion-related genes by modification of histone H3 (28) . We therefore assessed the binding of WHSC1 on Twist promoter. Chromatin immunoprecipitation assay verified that WHSC1 bound to the Twist promoter in both A549 and CL1-5 cells after resistin treatment ( Figure 4C ). Dimethylation of histone H3 at lysine 36 on the regions of the Twist promoter was thereby increased, whereas the trimethylation of histone H3 on the Twist promoter was decreased ( Figure 4D + DCs isolated from the lungs of lung cancer-bearing mice. Culture media and LLC were injected into the mice via the tail vein (control group, n = 10; LLC group, n = 8). After 14 days, non-tumorous and tumorous regions of the lungs were harvested. CD11c + DCs were isolated from fresh lung or tumor tissue, and resistin levels assessed by qRT-PCR. Resistin concentrations in supernatants of TADCs were assessed by enzyme-linked immunosorbent assay (ELISA). (E) Resistin high CD11c + DCs are found to have infiltrated cancer sections. Non-tumorous and tumorous regions (n = 10) were cut, stained and then analyzed by confocal microscopy. (F) High levels of resistin have also been found in the serum of lung cancer patients. Resistin levels in the sera of lung cancer patients (n = 46) and healthy donors (n = 24) were assessed by ELISA. Each value is the mean ± SD of three determinations. The asterisk indicates a significant difference between the two test groups, as analyzed by Student's t-test (*P < 0.05).
Online). Selective genetic inhibition of WHSC1 abrogated the resistin-mediated upregulation of Twist and H3K36me2 in cancer cells ( Figure 4F ). In addition, specific knockdown of WHSC1 expression by WHSC1 siRNA decreases cell migration and invasion in resistintreated cells (Figure 4G and 4H) . These data suggest that WHSC1 is an upstream event of Twist, and that it is involved in resistin-mediated cancer progression.
We next investigated the role of Twist on resistin-mediated cell migration and invasion by siRNA transfection. As shown in Figure 5A , in comparison with control siRNA, Twist1 siRNA reduced Twist expression by ~80%. Inhibition of Twist1 by siRNA transfection blocks the resistin-mediated downregulation of E-cadherin in cancer cells ( Figure 5B ). Furthermore, Twist1 siRNA also decreases resistin-mediated cancer cell migration and invasion ( Figure 5C and D) .
Resistin antibodies decrease cancer metastasis in vivo
We next used animal experiments to determine the role of resistin in lung cancer metastasis in mice. Mouse lung cancer cell line LLC was injected via tail vein, then the cells were allowed to grow in The invasiveness and migration ability of A549 and CL1-5 cells were quantified as described above. Resistin (1 or 10 ng/ml) acts as a chemoattractant of cancer migration and invasion and increases osteoclast differentiation (E) and activity (F). Peripheral blood mononuclear cells were treated with resistin (10 ng/ml) presenting in receptor activator of nuclear factor kappa-B ligand (100 ng/ml) and macrophage colony-stimulating factor (200 ng/ml) for 21 days. Osteoclast cells were stained for TRAP activity, and bone resorption activity determined by bone resorption assay kit. Each value is the mean ± SD of three determinations. The asterisk indicates a significant difference compared with the controls, as analyzed by Student's t-test (*P < 0.05). the lungs in vivo. As shown in Figure 6A , treatment of mice with recombinant mouse resistin protein increased lung metastasis by ~1.8-fold. In short, recombinant mouse resistin protein administration increased cancer cells' invasiveness ( Figure 6B) . Compared with the control group of mice, recombinant mouse resistin protein treatment also increased the WHSC1 and Twist expression as well as H3K36 dimethylation in tumor tissue isolated from the lungs of mice ( Figure 6C) .
Finally, we assessed whether inhibiting resistin generated from tumor-infiltrated DCs could decrease lung cancer development. Treatment of mice with anti-mouse resistin antibodies inhibited the growth of LLC in 71.4% (five of seven) of the mice, compared with 100% (seven of seven) of goat immunoglobulin G-treated control mice. In addition, anti-mouse resistin antibodies decreased the tumor nodules of the lungs in mice ( Figure 6D ). LLC was observed in cancer cells invading the surrounding tissue, whereas the invasiveness of LLC was decreased by inhibiting resistin ( Figure 6E ).
Discussion
Lung cancer is one of the most common cancers in developed and developing countries (1-3,29) . In the present study, we found that resistin, produced by cancer-infiltrating DCs, was able to increase the migration and invasiveness of lung cancer. Furthermore, resistin also shows a direct stimulatory effect on the differentiation of osteoclasts, which is an important pathological factor for the development of bone metastasis in lung cancer. These findings suggest that TADC-derived resistin may be a novel candidate in enhancing the development of lung cancer.
Resistin is a recently identified adipocyte-derived hormone that was originally thought to link obesity with diabetes (10, 30) . Resistin is upregulated in some cancers, such as breast, colon and prostate cancer, and higher levels are also associated with the highest histological grade (17) (18) (19) (20) 31, 32) . Resistin has been reported to increase the proliferation of prostate cancer by activating PI3K/AKT signaling (31) . It has also been indicated that resistin increases the expression of metalloproteinases, decreases the synthesis of tissue inhibitors of metalloproteinase production and thereby enhances the invasiveness of trophoblast-like cells (33) . In humans, adipose tissue is not the primary source of resistin and resistin-like molecules, which are instead secreted by peripheral blood mononuclear cells, macrophages, bone marrow and pancreatic cells (32) . Our results show that the source of resistin production is secretion from tumor-surrounding DCs. TADCs produce high levels of resistin, thereby increasing lung cancer migration and invasion and causing lung cancer cells to undergo EMT. Neutralization of resistin by antibodies, however, prevents this . A549 or CL1-5 cells were seeded in the upper insert and treated with or without antihuman resistin antibodies (2 μg/ml) or IgG (2 μg/ml), then TADC-CM (20%) was added to the lower well to act as a chemoattractive agent for 24 h. The migratory and invasive cells were quantified as described above. Peripheral blood mononuclear cells were treated with mdDC or TADC-CMs presenting in receptor activator of nuclear factor kappa-B ligand (100 ng/ml) and macrophage colony-stimulating factor (200 ng/ml) for 21 days. Osteoclast cells were stained for TRAP activity. Each value is the mean ± SD of three determinations. The asterisk indicates a significant difference between the two test groups, as analyzed by Student's t-test (*P < 0.05).
effect of TADCs on cancer progression. Moreover, TADC-derived resistin increases osteoclast differentiation and bone resorption activity, which suggests that TADC-derived resistin is responsible for the development of osteolytic bone metastasis. Investigation of the paradoxical roles of DCs in lung cancer development and malignant pathogenesis is very important for gaining insight into the intact tumor microenvironment.
Interestingly, we have found that resistin-producing CD11c + DCs infiltrate the lungs of LLC-bearing mice. In addition, CD11c
+ DCs surrounding lung cancer tissue also release high amounts of resistin Blockade of WHSC1 prevents resistin-mediated Twist upregulation (F), cell migration (G) and invasion (H). Cells were transfected with either control siRNA or WHSC1 siRNA, and the efficacy of siRNA was assessed by qRT-PCR. siRNA-transfected cells were treated with resistin (10 ng/ml) for the specified times (Twist and histone methylation, 6 h; cell migration, 48 h; invasion, 48 h). Protein levels were assessed by immunoblot assays. Cell migration and invasion were assessed by QCM™ 24-well Cell Migration and Invasion Assay kits. Dimethylation and trimethylation of histone H3 and H4 were assessed by chromatin immunoprecipitation assay. Each value is the mean ± SD of three determinations. The asterisk indicates a significant difference between the two test groups, as analyzed by Student's t-test (*P < 0.05).
compared with CD11c
+ DCs in non-tumorous tissue. Levels of resistin in the serum of lung cancer patients are also higher than those of healthy donors. Moreover, resistin increases the metastasis of LLC in vivo, whereas resistin antibody-based antagonism reduces the occurrence of LLC in mice. These results have been consistently observed in cell culture studies and, more importantly, in animal and human specimens. These findings provide unique evidence that TADCs enhance the development of lung cancer by secreting the tumorigenic factor resistin.
Twist is a class II member of the basic helix-loop-helix transcription factor essential for regulating EMT, a process required for enhancement of cell mobility (34, 35) . Twist is upregulated in various human solid cancers and is strongly associated with cancer invasion and metastasis (36) . Twist binds the E-box DNA elements of specific gene promoters, resulting in the repression of E-cadherin expression (34) . In this study, we found that treatment of A549 and CL1-5 lung cancer cells with resistin results in an increase in Twist expression and a decrease in E-cadherin. Inhibition of Twist expression by specific siRNA transfection decreases the effects of resistin on cell migration and E-cadherin upregulation in both A549 and CL1-5 cells, suggesting that the activation of Twist signaling plays a crucial role in the development of lung cancer growth and metastasis-induced TADCs or resistin.
WHSC1 (also known as NSD2 or MMSET), located at chromosome 4p16.3, encodes a histone lysine methyltransferase (37) . WHSC1 acts as a transcriptional regulator and interacts with developmental transcription factors whose defects overlap with the human disease WolfHirschhorn syndrome (38) . Dimethylation of histone H3 at lysine 36 (H3K36me2) is associated with actively transcribed regions and has been implicated as the mechanism for continuing transcription (39) . WHSC1 is ubiquitously expressed in early development embryonic tissues, whereas it is silent in most healthy adult tissues except for the thymus and testes (36) (37) (38) (39) . WHSC1 has been found to be overexpressed in various types of carcinomas, and elevation of WHSC1 has been shown to promote cellular growth, migration, invasion and tumorigenicity in multiple myeloma, glioblastoma and prostate cancers (28, 40) . WHSC1 triggers oncogenic Wnt and nuclear factor-κB signaling by increasing trimethylation of histone H3 at lysine 36, thus promoting cancer development (28, 41) . In our study, we found that treating A549 and CL1-5 cells with resistin dramatically increases the expression of WHSC1, in turn enhancing the dimethylation of histone H3 at lysine 36, resulting in an increase of Twist expression. Furthermore, selective inhibition of WHSC1 by siRNA transfection also decreases the effects of resistin on cell migration, invasion and E-cadherin downregulation, suggesting that the phenotypic transition of lung cancer by TADCs involves resistin-mediated WHSC1 upregulation and subsequent WHSC1-mediated Twist gene expression by epigenetic modification.
In summary, our results show a new mechanism for lung cancer progression, in which TADC-derived resistin promotes phenotypic transition and reinforces cancer progression. Resistin enhances the expression of WHSC1 and subsequently increases the expression of Twist by epigenetic modification, resulting in enhanced lung cancer development ( Figure 6F ). Inhibition of resistin by neutralization antibodies significantly reduces the incidence of cancer development in mice. Our findings suggest a new molecular determinant to target the vicious cycle of DCs and cancer and provide a new rationale for using antiresistin strategies to target aggressive invasive lung cancer. . Cells were transfected with control siRNA or Twist1 siRNA and then treated with resistin (10 ng/ml) for the indicated times (24 h for E-cadherin, and 48 h for cell migration and invasion assay). Twist1 mRNA levels were assessed by RT-PCR after 48 h transfection. The invasiveness and migration ability of A549 and CL1-5 cells were quantified by QCM™ 24-well Cell Migration and Invasion assay. The asterisk indicates a significant difference with the control, as analyzed by analysis of variance with Student's t-test post hoc (*P < 0.05). All experiments were performed independently at least three times.
